In recent trading session, Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) saw 1.22 million shares changing hands at last check today with its beta currently measuring 1.07. Company’s recent per share price level of $9.53 trading at -$0.13 or -1.29% at last check today assigns it a market valuation of $2.00B. That most recent trading price of BCRX’s stock is at a discount of -18.68% from its 52-week high price of $11.31 and is indicating a premium of 36.94% from its 52-week low price of $6.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.33 million shares which gives us an average trading volume of 4.50 million if we extend that period to 3-months.
For Biocryst Pharmaceuticals Inc (BCRX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.17. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.07 in the current quarter.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
Upright in the red during last session for losing -1.29%, in the last five days BCRX remained trading in the red while hitting it’s week-highest on Tuesday, 06/24/25 when the stock touched $9.53 price level, adding 5.27% to its value on the day. Biocryst Pharmaceuticals Inc’s shares saw a change of 56.83% in year-to-date performance and have moved -5.59% in past 5-day. Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) showed a performance of -9.71% in past 30-days. Number of shares sold short was 23.08 million shares which calculate 5.52 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a rise of 40.44% to its recent value today. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 25. It follows that stock’s current price would jump 26.55% in reaching the projected high whereas dropping to the targeted low would mean a gain of 26.55% for stock’s current value.
Biocryst Pharmaceuticals Inc (BCRX) estimates and forecasts
This year revenue growth is estimated to rise 36.18% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 149.53M for the same. And 10 analysts are in estimates of company making revenue of 156.51M in the next quarter. Company posted 109.33M and 117.08M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 14.52% during past 5 years.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
Insiders are in possession of 1.20% of company’s total shares while institution are holding 85.56 percent of that, with stock having share float percentage of 86.59%. Investors also watch the number of corporate investors in a company very closely, which is 85.56% institutions for Biocryst Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at BCRX for having 19.96 million shares of worth $123.33 million. And as of 2024-06-30, it was holding 9.6676 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 18.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.0926 of outstanding shares, having a total worth of $116.0 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 6.55 shares of worth $62.4 million or 3.13% of the total outstanding shares. The later fund manager was in possession of 5.06 shares on Apr 30, 2025 , making its stake of worth around $48.2 million in the company or a holder of 2.42% of company’s stock.
